查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2080405

消化器官系統藥物市場：2026-2032年全球市場預測（依藥物類別、給藥途徑、分子類型、劑型、適應症、最終用戶和分銷管道分類）

Gastrointestinal Drugs Market by Drug Class, Route Of Administration, Molecule Type, Formulation Type, Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，消化器官系統藥物市場將成長至 902.6 億美元，複合年成長率為 5.45%。

主要市場統計數據
基準年 2025 622.3億美元
預計年份：2026年 654.5億美元
預測年份：2032年 902.6億美元
複合年成長率 (%) 5.45%

由於消化器官系統疾病影響範圍廣泛，包括胃食道逆流、消化性潰瘍、大腸激躁症躁症、發炎性腸道疾病、便秘、腹瀉、噁心嘔吐、肝臟相關併發症以及檢查和手術前的腸道準備等，因此胃腸道藥物仍然是專科和基層醫療領域的核心成長點。人口老化、診斷率提高、微生物組學的發展以及治療策略從症狀控制轉向緩解疾病和長期疾病管理，都是推動消化器官系統藥物需求成長的主要因素。

該市場涵蓋成熟的小分子藥物類別，例如質子幫浦抑制劑、H2受體拮抗劑、瀉藥、止瀉藥、解痙藥、止吐藥和膽汁酸療法，以及生物製藥、生物相似藥、標靶免疫調節劑和基於微生物組的療法。競爭優勢越來越依賴差異化的臨床療效、對支付方至關重要的證據、耐受性、給藥便利性、對藥物依從性的支持，以及能夠同時解決大規模胃腸道疾病和需要長期治療的嚴重慢性疾病的能力。

消化器官系統藥物市場的變革性變化

精準醫療、生技藥品之間的競爭以及真實世界數據（REW）的日益普及正在重塑消化器官系統藥物市場格局。在發炎性腸道疾病領域，治療方案正從廣泛的抗發炎控制轉向整合素抑制、白細胞介素通道調節、 Janus激酶抑制、鞘氨醇-1-磷酸受體調節以及生物相似藥的應用等機制。在功能性胃腸道疾病領域，患者報告結局、症狀頻率、腹痛減輕、排便習慣正常化以及生活品質（QOL）評估正成為產品差異化的關鍵指標。

人工智慧（AI）的累積影響

人工智慧 (AI) 正在加速消化器官系統醫學各個領域的變革，從藥物發現和臨床開發到藥物安全監測和商業化。 AI 驅動的標靶識別支持基因組學、蛋白質組學、代謝體學、微生物組資料集、影像學結果和發炎通道分析，幫助研究人員優先研究具有生物統計學意義的機制。在臨床試驗中，機器學習可以改善實驗室選擇、患者分層、終點預測、方案可行性評估以及受試者招募，尤其適用於克隆氏症、潰瘍性大腸炎、大腸激躁症麻痺和功能性消化不良等症狀表現多樣的疾病。

關鍵區域洞察

北美憑藉其高度專業化的醫療保健基礎設施、生物製藥的高主導、活躍的臨床試驗以及完善的新藥、生物類似藥和基於微生物組的療法的FDA核准流程，仍然是消化器官系統醫學創新領域的領先地區。歐洲受益於其廣泛的公共醫療保險報銷體系、透過EMA進行的協調監管審查以及強大的胃腸病學網路，但其市場准入決策高度重視醫療技術評估、成本效益、與生物類似藥的競爭以及真實世界療效的證據。

關鍵區域洞察

在印尼、泰國、越南、馬來西亞、新加坡和菲律賓，不斷擴大的醫療保險覆蓋範圍、私人醫院網路、診斷技術和專科醫生隊伍，使得東協在消化器官系統藥物的可及性方面日益重要。在海灣合作理事會（GCC）國家，對高品質療法的需求強勁，這得益於國家醫療保健投資、高額的專科醫療支出、數位醫療的現代化以及旨在加強本地製藥能力的政策。歐盟在實證藥物可及性方面繼續發揮關鍵作用，其集中監管和國家報銷決策既擴大了消化器官系統藥物（尤其是生技藥品、生物類似藥和先進療法）的規模，又對其進行了嚴格的審查。

主要國家概況

美國在專科消化器官系統藥物支出、臨床試驗、臨床指南採納以及創新療法的快速推廣方面發揮主導作用。而加拿大則著重於醫療技術評估、報銷審查以及各省之間的公平取得。墨西哥和巴西是拉丁美洲的重要市場，這兩個國家中產階級醫療保健需求不斷成長，私部門的醫療服務取得管道也日益暢通，但同時處方藥清單、分銷和定價方面也存在諸多限制。在歐洲，英國、德國、法國、義大利和西班牙構成了主要的醫療服務取得環境，這主要受各自醫療保健體系、衛生技術評估要求、參考定價體系、相容性法規以及生物類似藥日益普及的影響。同時，在俄羅斯，對本地生產和進口的專科藥物的需求仍然強勁。

業界領導者使用的實用建議

產業領導者應優先考慮差異化機制、可衡量的結果以及能夠抵禦學名藥和生物相似藥競爭壓力的生命週期策略。成功的產品系列應將大宗消化器官系統與針對發炎性腸道疾病、功能性腸道疾病、腸道菌叢相關疾病、肝臟相關併發症、酸相關疾病和動力障礙的專科藥物結合。企業應設計包含與支付方相關的終點指標的臨床試驗，例如臨床緩解、內視鏡改善、停用荷爾蒙狀態、住院次數減少、復發率降低、治療連續性以及患者自述症狀改善。

調查方法

本執行摘要基於系統性的二手資料研究、監管審查、治療領域分析和跨區域市場評估。資訊來源，以及美國食品藥品監督管理局 (FDA)、歐洲藥品管理局 (EMA)、世界衛生組織 (WHO)、美國疾病控制與預防中心 (CDC)、美國國立衛生研究院 (NIH) 和國家衛生組織等權威權威資訊來源的資訊。

結論

消化器官系統藥物市場正從成熟的基層醫療領域向多層次的治療格局演變，其特點是專科創新、生物製藥、生物類似藥、微生物組學、精準醫療和人工智慧驅動的證據生成。高發病支撐著基本需求，而慢性免疫介導性疾病、功能性疾病、酸相關疾病和運動功能障礙則為差異化療法和長期患者管理創造了機會。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：消化器官系統市場：依藥物類別分類

  • 制酸劑
    • 氫氧化鋁
    • 碳酸鈣
    • 氫氧化鎂
    • 碳酸氫鈉
  • 止瀉藥
    • 次水楊酸鉍
    • 洛哌丁胺
  • 解痙藥
    • 二環胺
    • 莨菪鹼
  • 瀉藥
  • 質子幫浦抑制劑
    • 奧美拉唑
    • Esomeprazole
    • 蘭索拉唑
    • Rabeprazole
  • 運動興奮劑
    • 多巴胺拮抗劑
    • 血清素 5-HT4促效劑
    • 大環內酯類運動興奮劑
  • 止吐藥
    • Ondansetron
    • 丙氯拉嗪

第8章：消化器官系統藥物市場：依給藥途徑分類

  • 注射藥物
    • 肌肉內部
    • 靜脈
  • 口服
    • 膠囊
      • 硬殼
      • 軟凝膠
    • 粉末
    • 藥片
  • 直腸給藥

第9章：消化器官系統藥物市場：依分子類型分類

  • 低分子
  • 生物製劑
  • 生物相似藥
  • 胜肽
  • 酵素替代療法
  • 重組蛋白
  • 生物醫學治療

第10章：消化器官系統藥物市場：以劑型分類

  • 速釋製劑
  • 緩釋製劑
  • 腸溶衣
  • 固定劑量組合藥物
  • 液體

第11章：消化器官系統藥物市場：依適應症分類

  • 便秘
  • 胃食道逆流症
  • 腹瀉
  • 大腸激躁症
  • 消化性潰瘍
  • 發炎性腸道疾病
    • 克隆氏症
    • 潰瘍性大腸炎
  • 胃輕癱

第12章：消化器官系統藥物市場：依最終用戶分類

  • 診所
    • 胃腸病診所
    • 一般診所
  • 家庭醫療保健
  • 醫院

第13章：消化器官系統藥物市場：依分銷管道分類

  • 離線
    • 醫院藥房
    • 零售藥房
    • 專科藥房
  • 網路藥房

第14章：消化器官系統藥物市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章：消化器官系統藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：消化器官系統藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb
  • Cipla Limited
  • Cosmo Pharmaceuticals NV
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Ferring International Center SA
  • GlaxoSmithKline plc
  • Ironwood Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Reckitt Benckiser Group plc
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-434CCDA051D0

The Gastrointestinal Drugs Market is projected to grow by USD 90.26 billion at a CAGR of 5.45% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 62.23 billion
Estimated Year [2026] USD 65.45 billion
Forecast Year [2032] USD 90.26 billion
CAGR (%) 5.45%

Gastrointestinal drugs remain a core growth area in specialty and primary care because digestive diseases affect large patient populations across gastroesophageal reflux disease, peptic ulcer disease, irritable bowel syndrome, inflammatory bowel disease, constipation, diarrhea, nausea and vomiting, liver-linked complications, and procedure-related bowel preparation. Demand is reinforced by aging demographics, higher diagnosis rates, microbiome science, and the shift from symptom suppression toward disease modification and long-term disease control.

The market spans mature small-molecule categories such as proton pump inhibitors, H2 receptor antagonists, laxatives, antidiarrheals, antispasmodics, antiemetics, and bile acid therapies, alongside biologics, biosimilars, targeted immunomodulators, and microbiota-based therapeutics. Competitive advantage increasingly depends on differentiated clinical outcomes, payer-relevant evidence, tolerability, convenient administration, adherence support, and the ability to serve both high-volume gastrointestinal conditions and severe chronic diseases requiring long-term therapy.

Transformative Shifts in the Gastrointestinal Drugs Landscape

The gastrointestinal drugs landscape is being reshaped by precision medicine, biologic competition, and growing use of real-world evidence. In inflammatory bowel disease, therapeutic selection is moving beyond broad anti-inflammatory control toward mechanisms such as integrin inhibition, interleukin pathway modulation, Janus kinase inhibition, sphingosine-1-phosphate receptor modulation, and biosimilar adoption. In functional gastrointestinal disorders, patient-reported outcomes, symptom frequency, abdominal pain reduction, bowel habit normalization, and quality-of-life measures are becoming central to product differentiation.

Another major shift is the expansion of microbiome-based approaches and combination care models that link diagnostics, nutrition, digital monitoring, endoscopy, and pharmacotherapy. At the same time, generic erosion in legacy acid-suppression, antiemetic, and motility categories is increasing pricing pressure, pushing manufacturers to invest in specialty indications, novel delivery systems, fixed-dose strategies, and evidence packages that demonstrate reduced hospital utilization, fewer disease flares, improved remission durability, and better long-term adherence.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is compounding change across gastrointestinal drug discovery, clinical development, pharmacovigilance, and commercialization. AI-enabled target identification supports analysis of genomics, proteomics, metabolomics, microbiome datasets, imaging outputs, and inflammatory pathways, helping researchers prioritize mechanisms with stronger biological plausibility. In clinical trials, machine learning can improve site selection, patient stratification, endpoint prediction, protocol feasibility, and recruitment for diseases with heterogeneous presentation such as Crohn's disease, ulcerative colitis, irritable bowel syndrome, gastroparesis, and functional dyspepsia.

The cumulative impact is also visible in post-market surveillance and medical engagement. AI can detect adverse-event signals across structured and unstructured data, support claims-based outcomes research, identify adherence barriers, and personalize educational content for physicians and patients. However, leaders must manage data quality, algorithm transparency, bias control, privacy compliance, cybersecurity, and regulatory expectations to ensure AI improves evidence generation without weakening scientific rigor or patient trust.

Key Regional Insights

North America remains a leading region for gastrointestinal drug innovation due to advanced specialty care infrastructure, high use of biologics, substantial clinical trial activity, and established FDA pathways for novel drugs, biosimilars, and microbiota-based therapies. Europe benefits from broad public reimbursement systems, coordinated regulatory review through the EMA, and strong gastroenterology networks, while access decisions place heavy emphasis on health technology assessment, cost-effectiveness, biosimilar competition, and real-world outcomes evidence.

Asia-Pacific is gaining strategic importance as China, India, Japan, South Korea, and Australia expand diagnosis, clinical research participation, endoscopic capacity, and access to specialty gastrointestinal therapies. Latin America shows rising demand in Brazil, Mexico, and regional private healthcare systems, although affordability, public formulary inclusion, and reimbursement variability influence uptake. The Middle East is investing in advanced hospitals and specialty care, especially across GCC markets, while Africa presents long-term access opportunities shaped by essential medicines availability, infectious gastrointestinal disease burden, local distribution capacity, and expanding urban healthcare infrastructure.

Key Group Insights

ASEAN is becoming more relevant for gastrointestinal drug access as Indonesia, Thailand, Vietnam, Malaysia, Singapore, and the Philippines expand healthcare coverage, private hospital networks, diagnostics, and specialist capacity. The GCC shows strong demand for premium therapies supported by national health investment, high specialty-care spending, digital health modernization, and a policy focus on local pharmaceutical capability. The European Union remains critical for evidence-driven access, where centralized regulation and national reimbursement decisions create both scale and scrutiny for gastrointestinal drugs, particularly biologics, biosimilars, and advanced therapies.

BRICS markets combine large patient populations with expanding domestic pharmaceutical capacity, making China, India, Brazil, Russia, and South Africa important for volume access, clinical development, and manufacturing resilience. G7 countries continue to set standards for innovation, pricing debate, pharmacovigilance, patient safety, and evidence-based prescribing. NATO-aligned markets are significant because supply security, regulatory alignment, medicine stockpiling, and resilient access to essential and specialty medicines have become more prominent healthcare priorities following recent global supply disruptions.

Key Country Insights

The United States leads in specialty gastrointestinal drug spending, clinical trials, guideline adoption, and rapid uptake of innovative therapies, while Canada emphasizes health technology assessment, reimbursement review, and equitable provincial access. Mexico and Brazil are important Latin American markets where expanding middle-class healthcare demand and private-sector access coexist with formulary, distribution, and affordability constraints. In Europe, the United Kingdom, Germany, France, Italy, and Spain represent major access environments shaped by national health systems, HTA requirements, reference pricing, prescribing controls, and increasing biosimilar use, while Russia maintains demand for both local production and imported specialty medicines.

China and India are central to future gastrointestinal drug access because of scale, improving diagnosis, domestic manufacturing, biosimilar development, and greater participation in global clinical development. Japan remains a sophisticated market with strong clinical standards, aging-related gastrointestinal demand, and disciplined reimbursement review, while South Korea is recognized for advanced healthcare infrastructure, biosimilars, digital hospital systems, and clinical research capability. Australia adds value through transparent reimbursement processes, specialist networks, pharmacovigilance standards, and high expectations for evidence-based prescribing.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated mechanisms, measurable outcomes, and lifecycle strategies that withstand generic and biosimilar pressure. Successful portfolios will combine high-volume gastrointestinal therapies with specialty assets in inflammatory bowel disease, functional bowel disorders, microbiome-related disease, liver-associated complications, acid-related disorders, and motility disorders. Companies should design trials with payer-relevant endpoints, including clinical remission, endoscopic improvement, steroid-free response, reduced hospitalization, lower flare frequency, treatment persistence, and patient-reported symptom improvement.

Commercial teams should build region-specific access strategies, invest in real-world evidence, and strengthen physician education around diagnosis, treatment sequencing, switching, adherence, and safety monitoring. Manufacturing leaders should secure active pharmaceutical ingredient supply, expand quality oversight, improve cold-chain readiness for biologics, and evaluate local production partnerships in fast-growing markets. AI should be deployed through governed frameworks that align data science, medical affairs, regulatory, legal, compliance, cybersecurity, and pharmacovigilance functions.

Research Methodology

This executive summary is based on structured secondary research, regulatory review, therapeutic-area analysis, and cross-regional market assessment. Inputs include publicly available information from health authorities, clinical trial registries, peer-reviewed medical literature, prescribing guidance, drug labels, treatment guidelines, reimbursement frameworks, and recognized public health sources such as the FDA, EMA, WHO, CDC, NIH, and national health agencies.

The methodology emphasizes verified, data-backed interpretation rather than speculative projections. Market dynamics were assessed across disease burden, product class maturity, clinical innovation, regulatory pathways, reimbursement pressure, competitive intensity, biosimilar adoption, regional access conditions, supply-chain resilience, and technology adoption. Insights were synthesized to support executive decision-making for pharmaceutical manufacturers, healthcare investors, distributors, payers, providers, and policy stakeholders.

Conclusion

The gastrointestinal drugs market is evolving from a mature primary-care category into a multi-layered therapeutic landscape defined by specialty innovation, biologics, biosimilars, microbiome science, precision medicine, and AI-enabled evidence generation. High-prevalence conditions sustain baseline demand, while chronic immune-mediated, functional, acid-related, and motility disorders create opportunities for differentiated therapies and long-term patient management.

Future leadership will depend on clinical relevance, access strategy, manufacturing resilience, regulatory readiness, and credible real-world outcomes. Companies that align scientific innovation with affordability, regional execution, patient-centered evidence, and digital intelligence will be best positioned to capture sustainable growth in gastrointestinal therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Gastrointestinal Drugs Market, by Drug Class

  • 7.1. Antacids
    • 7.1.1. Aluminum Hydroxide
    • 7.1.2. Calcium Carbonate
    • 7.1.3. Magnesium Hydroxide
    • 7.1.4. Sodium Bicarbonate
  • 7.2. Antidiarrheals
    • 7.2.1. Bismuth Subsalicylate
    • 7.2.2. Loperamide
  • 7.3. Antispasmodics
    • 7.3.1. Dicyclomine
    • 7.3.2. Hyoscyamine
  • 7.4. Laxatives
  • 7.5. Proton Pump Inhibitors
    • 7.5.1. Omeprazole
    • 7.5.2. Esomeprazole
    • 7.5.3. Lansoprazole
    • 7.5.4. Rabeprazole
  • 7.6. Prokinetics
    • 7.6.1. Dopamine Antagonists
    • 7.6.2. Serotonin 5-HT4 Agonists
    • 7.6.3. Macrolide Prokinetics
  • 7.7. Antiemetics
    • 7.7.1. Ondansetron
    • 7.7.2. Prochlorperazine

8. Gastrointestinal Drugs Market, by Route Of Administration

  • 8.1. Injectable
    • 8.1.1. Intramuscular
    • 8.1.2. Intravenous
  • 8.2. Oral
    • 8.2.1. Capsules
      • 8.2.1.1. Hard Shell
      • 8.2.1.2. Soft Gel
    • 8.2.2. Powders
    • 8.2.3. Tablets
  • 8.3. Rectal

9. Gastrointestinal Drugs Market, by Molecule Type

  • 9.1. Small Molecule
  • 9.2. Biologic
  • 9.3. Biosimilar
  • 9.4. Peptide
  • 9.5. Enzyme Replacement
  • 9.6. Recombinant Protein
  • 9.7. Live Biotherapeutic

10. Gastrointestinal Drugs Market, by Formulation Type

  • 10.1. Immediate Release
  • 10.2. Extended Release
  • 10.3. Enteric Coated
  • 10.4. Fixed Dose Combination
  • 10.5. Liquid Formulation

11. Gastrointestinal Drugs Market, by Indication

  • 11.1. Constipation
  • 11.2. Gastroesophageal Reflux Disease
  • 11.3. Diarrhea
  • 11.4. Irritable Bowel Syndrome
  • 11.5. Peptic Ulcer Disease
  • 11.6. Inflammatory Bowel Disease
    • 11.6.1. Crohn's Disease
    • 11.6.2. Ulcerative Colitis
  • 11.7. Gastroparesis

12. Gastrointestinal Drugs Market, by End User

  • 12.1. Clinics
    • 12.1.1. Gastroenterology Clinics
    • 12.1.2. General Practice Clinics
  • 12.2. Home Healthcare
  • 12.3. Hospitals

13. Gastrointestinal Drugs Market, by Distribution Channel

  • 13.1. Offline
    • 13.1.1. Hospital Pharmacies
    • 13.1.2. Retail Pharmacies
    • 13.1.3. Specialty Pharmacies
  • 13.2. Online Pharmacies

14. Gastrointestinal Drugs Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Gastrointestinal Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Gastrointestinal Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. AbbVie Inc.
  • 18.2. Amgen Inc.
  • 18.3. AstraZeneca PLC
  • 18.4. Bausch Health Companies Inc.
  • 18.5. Bayer AG
  • 18.6. Boehringer Ingelheim International GmbH
  • 18.7. Bristol-Myers Squibb
  • 18.8. Cipla Limited
  • 18.9. Cosmo Pharmaceuticals N.V.
  • 18.10. Dr. Reddy's Laboratories Ltd.
  • 18.11. Eli Lilly and Company
  • 18.12. F. Hoffmann-La Roche Ltd
  • 18.13. Ferring International Center S.A.
  • 18.14. GlaxoSmithKline plc
  • 18.15. Ironwood Pharmaceuticals, Inc.
  • 18.16. Johnson & Johnson Services, Inc.
  • 18.17. Merck & Co., Inc.
  • 18.18. Novartis AG
  • 18.19. Otsuka Pharmaceutical Co., Ltd.
  • 18.20. Pfizer Inc.
  • 18.21. Reckitt Benckiser Group plc
  • 18.22. Sanofi S.A.
  • 18.23. Takeda Pharmaceutical Company Limited
  • 18.24. Teva Pharmaceutical Industries Ltd.
  • 18.25. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GASTROINTESTINAL DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL GASTROINTESTINAL DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL GASTROINTESTINAL DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL GASTROINTESTINAL DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL GASTROINTESTINAL DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL GASTROINTESTINAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTACIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTACIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTACIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ALUMINUM HYDROXIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ALUMINUM HYDROXIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ALUMINUM HYDROXIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CALCIUM CARBONATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CALCIUM CARBONATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CALCIUM CARBONATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MAGNESIUM HYDROXIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MAGNESIUM HYDROXIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MAGNESIUM HYDROXIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SODIUM BICARBONATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SODIUM BICARBONATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SODIUM BICARBONATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIDIARRHEALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIDIARRHEALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTIDIARRHEALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BISMUTH SUBSALICYLATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BISMUTH SUBSALICYLATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BISMUTH SUBSALICYLATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LOPERAMIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LOPERAMIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LOPERAMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTISPASMODICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTISPASMODICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTISPASMODICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DICYCLOMINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DICYCLOMINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DICYCLOMINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HYOSCYAMINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HYOSCYAMINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HYOSCYAMINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LAXATIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LAXATIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LAXATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PROTON PUMP INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PROTON PUMP INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PROTON PUMP INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OMEPRAZOLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OMEPRAZOLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OMEPRAZOLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LANSOPRAZOLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LANSOPRAZOLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LANSOPRAZOLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RABEPRAZOLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RABEPRAZOLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RABEPRAZOLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PROKINETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PROKINETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PROKINETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DOPAMINE ANTAGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DOPAMINE ANTAGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DOPAMINE ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SEROTONIN 5-HT4 AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SEROTONIN 5-HT4 AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SEROTONIN 5-HT4 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MACROLIDE PROKINETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MACROLIDE PROKINETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MACROLIDE PROKINETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTIEMETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIEMETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTIEMETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ONDANSETRON MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ONDANSETRON MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ONDANSETRON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PROCHLORPERAZINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PROCHLORPERAZINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PROCHLORPERAZINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HARD SHELL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HARD SHELL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HARD SHELL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL SOFT GEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SOFT GEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL SOFT GEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL POWDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL POWDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL POWDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL RECTAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL RECTAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL RECTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL SMALL MOLECULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL SMALL MOLECULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL SMALL MOLECULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BIOLOGIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIOLOGIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BIOLOGIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIOSIMILAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BIOSIMILAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIOSIMILAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PEPTIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PEPTIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ENZYME REPLACEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ENZYME REPLACEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ENZYME REPLACEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL RECOMBINANT PROTEIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL RECOMBINANT PROTEIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL RECOMBINANT PROTEIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL LIVE BIOTHERAPEUTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL LIVE BIOTHERAPEUTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL LIVE BIOTHERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL IMMEDIATE RELEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL IMMEDIATE RELEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL IMMEDIATE RELEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL EXTENDED RELEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL EXTENDED RELEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL EXTENDED RELEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ENTERIC COATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ENTERIC COATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ENTERIC COATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL FIXED DOSE COMBINATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL FIXED DOSE COMBINATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL FIXED DOSE COMBINATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL LIQUID FORMULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL LIQUID FORMULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL LIQUID FORMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CONSTIPATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CONSTIPATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL DIARRHEA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL DIARRHEA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL DIARRHEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL IRRITABLE BOWEL SYNDROME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL IRRITABLE BOWEL SYNDROME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL IRRITABLE BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL PEPTIC ULCER DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL PEPTIC ULCER DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL PEPTIC ULCER DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL CROHN'S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL CROHN'S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL CROHN'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL GASTROPARESIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL GASTROPARESIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL GASTROPARESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL GASTROENTEROLOGY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL GASTROENTEROLOGY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL GASTROENTEROLOGY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL GENERAL PRACTICE CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL GENERAL PRACTICE CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL GENERAL PRACTICE CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 226. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, 2018-2032 (USD MILLION)
  • TABLE 228. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, 2018-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, 2018-2032 (USD MILLION)
  • TABLE 230. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, 2018-2032 (USD MILLION)
  • TABLE 232. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 236. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 240. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, 2018-2032 (USD MILLION)
  • TABLE 248. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, 2018-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, 2018-2032 (USD MILLION)
  • TABLE 250. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, 2018-2032 (USD MILLION)
  • TABLE 252. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 254. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 256. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 260. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 264. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 286. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, 2018-2032 (USD MILLION)
  • TABLE 288. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, 2018-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, 2018-2032 (USD MILLION)
  • TABLE 290. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, 2018-2032 (USD MILLION)
  • TABLE 292. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 294. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 296. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 300. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 302. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 304. MIDDLE EAST GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 305. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 306. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 307. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, 2018-2032 (USD MILLION)
  • TABLE 308. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, 2018-2032 (USD MILLION)
  • TABLE 309. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, 2018-2032 (USD MILLION)
  • TABLE 310. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 311. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, 2018-2032 (USD MILLION)
  • TABLE 312. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 313. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 314. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 315. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 316. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 317. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 320. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 321. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 322. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 323. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 324. AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 325. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 326. ASEAN GASTROINTESTINAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 327. ASEAN GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 328. ASEAN GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, 2018-2032 (USD MILLION)
  • TABLE 329. ASEAN GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, 2018-2032 (USD MILLION)
  • TABLE 330. ASEAN GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, 2018-2032 (USD MILLION)
  • TABLE 331. ASEAN GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 332. ASEAN GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, 2018-2032 (USD MILLION)
  • TABLE 333. ASEAN GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 334. ASEAN GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 335. ASEAN GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 336. ASEAN GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 337. ASEAN GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 338. ASEAN GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 339. ASEAN GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 340. ASEAN GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 341. ASEAN GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 342. ASEAN GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 343. ASEAN GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 344. ASEAN GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 345. ASEAN GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 346. GCC GASTROINTESTINAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 347. GCC GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 348. GCC GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, 2018-2032 (USD MILLION)
  • TABLE 349. GCC GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, 2018-2032 (USD MILLION)
  • TABLE 350. GCC GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, 2018-2032 (USD MILLION)
  • TABLE 351. GCC GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 352. GCC GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, 2018-2032 (USD MILLION)
  • TABLE 353. GCC GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 354. GCC GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 355. GCC GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 356. GCC GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 357. GCC GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 358. GCC GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 359. GCC GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 360. GCC GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 361. GCC GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 362. GCC GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 363. GCC GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 364. GCC GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 365. GCC GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 366. EUROPEAN UNION GASTROINTESTINAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 367. EUROPEAN UNION GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 368. EUROPEAN UNION GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, 2018-2032 (USD MILLION)
  • TABLE 369. EUROPEAN UNION GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, 2018-2032 (USD MILLION)
  • TABLE 370. EUROPEAN UNION GASTROINTESTINAL DRUGS MARKET